Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 174 participants.

Also called NCT06290349

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06290349
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06290349. Randomized; double masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2025-09-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Intervention (Drug)
DA5221-T1
Intervention (Drug)
DA5221-T2
Intervention (Drug)
Placebo
Intervention (Drug)
DA5221-B1
Intervention (Drug)
DA5221-B2
Lead sponsor
Dong-A ST Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06290349
Content hash
0ba19b0143d2a57d821ebfc519f4461182a4efc43a275bae7a6f61d00fd6acf9